A year of COVID-19 GWAS results from the GRASP portal reveals potential SARS-CoV-2 modifiers

Florian Thibord[1], Melissa V. Chan[1], Ming-Huei Chen[1], Andrew D. Johnson[1,*]

[1] Division of Intramural Research, Population Sciences Branch, Framingham, MA 01702

*corresponding author: johnsonad2@nhlbi.nih.gov

Abstract

Host genetic variants influence the susceptibility and severity of several infectious diseases, and the discovery of novel genetic associations with Covid-19 phenotypes could help developing new therapeutic strategies to reduce its burden.

Between May 2020 and February 2021, we used Covid-19 data released periodically by UK Biobank and performed over 400 Genome-Wide Association Studies (GWAS) of Covid-19 susceptibility (N=15,738 cases), hospitalization (N=1,916), severe outcomes (N=935) and death (N=828), stratified by ancestry and sex.

In coherence with previous studies, we observed 2 independent signals at the chr3p21.31 locus (rs73062389-A, OR=1.22, $P=7.64\times10^{-14}$ and rs13092887-A, OR=1.73, $P=2.38\times10^{-8}$, in Europeans) modulating susceptibility and severity, respectively, and a signal influencing susceptibility at the *ABO* locus (rs9411378-A, OR=1.10, $P=7.36\times10^{-10}$, in Europeans), which was more significant in men than in women (P=0.01). In addition, we detected 7 genome-

wide significant signals in the last data release analyzed (on February 24th 2021), of which 4 were associated with susceptibility (*SCRT2*, *LRMDA*, chr15q24.2, *MIR3681HG*), 2 with hospitalization (*ANKS1A*, chr12p13.31) and 1 for severity (*ADGRE1*). Finally, we identified over 300 associations which increased in significance over time, and reached at least $P<10^{-5}$ in the last data release analyzed. We replicated 2 of these signals in an independent dataset: a variant downstream of *CCL3* (rs2011959) associated with severity in men, and a variant located in an *ATP5PO* intron (rs12482569) associated with hospitalization.

These results, freely available on the GRASP portal, provide new insights on the host genetic architecture of Covid-19 phenotypes.

Introduction

The severe acute respiratory syndrome – coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (Covid-19) which affects individuals with variable severity, ranging from asymptomatic patients to mild respiratory symptoms, hypercytokinemia, pneumonia, thrombosis and even death.[1,2] Understanding the mechanisms leading to heterogeneous symptoms and susceptibility is essential in order to develop efficient treatments and improve patient care. Host genetic diversity has been shown to influence the effects of infection to several viruses,[3] such as variations in *CCR5* [MIM: 601373] leading to HIV resistance[4] [MIM: 609423] or *IRF7* [MIM: 605047] deficiency affecting *Influenza* susceptibility [MIM: 614680].[5]

In order to discover human genetic determinants to Covid-19 susceptibility and severity, several biobanks and research groups worldwide collaborated to perform Genome-Wide

45 Association Studies (GWAS) and meta-analyses of the GWAS. In June 2020, a study involving
46 1,980 Covid-19 infected patients with respiratory failure was the first to reveal genome-wide
47 significant ($P < 5 \times 10^{-8}$) associations at the 3p21.31 locus, encompassing *SLC6A20* [MIM:
48 605616] and several chemokine receptors, and at the *ABO* [MIM: 110300] locus on
49 chromosome 9.[6] These 2 signals were later validated in independent analyses for both Covid-19
50 susceptibility and severity[7,8] while additional significant associations were observed at loci
51 involved in immune response or inflammation, such as *IFNAR2* [MIM: 602376], *DPP9* [MIM:
52 608258], *TYK2* [MIM: 176941], *CCHCR1* [MIM: 605310] and *OAS1* [MIM: 164350]. Notably,
53 these findings implicate common and uncommon variants, while studies trying to identify
54 associations of rare variants have been unsuccessful so far.[9] The largest effort is currently led by
55 the Covid-19 host genetics initiative (Covid-19hgi),[10] which completed meta-analyses of results
56 shared by 46 studies as of January 18th 2021, and plan to release new results as additional data
57 is made available. A major contributor to this group is the UK Biobank (UKB)[11] which
58 periodically releases the results of Covid-19 tests and related deaths, as well as health care data
59 for its nearly 500,000 consented participants, to approved researchers.
60 We created a public Covid-19 GWAS results portal
61 (https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx) in order to provide rapid deep
62 annotation for emerging genetics results and facilitate open access to the scientific community.
63 We contribute to this resource by performing GWAS on each Covid-19 data release from the UK
64 Biobank, including sex-specific, ancestry-specific, and trans-ethnic Covid-19 related GWAS,
65 along with a deep set of annotations for top variants (with $P < 1 \times 10^{-5}$). For each release, up to
66 65 GWAS have been generated including Covid-19 susceptibility, Covid-19 hospitalization,

severe Covid-19 with respiratory failure, and Covid-19 death. Here we describe the results of these GWAS, 434 in total as of February 24th 2021, and report the evolution of signals associated with these Covid-19 phenotypes over the consecutive datasets released by UKB since May 2020. The latter approach, tracking the evolution of genetic signatures iteratively in UKB, suggests a valuable new analytic approach in genetic biobank studies where emerging true signals may be identified before they reach genome-wide significance based on their trajectories of significance.

Materials and Methods

UK Biobank data

Analyses are based on v.3 of the UKB imputed dataset,[12] which provide genomic data for 487,320 participants from multiple ethnicities, including 459,250 of European ancestry (EUR), 7,644 of African ancestry (AFR), 9,417 of South Asian ancestry (SAS) and 11,009 of other ancestries (OTHERS). Participants were enrolled at ages ranging from 37 to 73 and are 51.16% female. UKB started to release Covid-19 test results of its participants on March 15th 2020, and periodically update this resource as new cases are reported. Furthermore, information about Covid-19 related death was made available from June 2020, while inpatient data and primary care data was first added during the summer of 2020 and are periodically updated. Details regarding the definition and selection of cases with Covid-19 susceptibility, Covid-19 hospitalization, Covid-19 severity, and Covid-19 death are available in **Table S1**.

Phenotype definition

Depending on the Covid-19 phenotype analyzed (susceptibility, hospitalization, severity, or death), up to 3 different subsets of participants were used as controls. For Covid-19 susceptibility, cases with positive test results were analyzed against either participants tested with negative results (labelled Tested), or against all participants without a positive test (labelled Population). For analyses of Covid-19 hospitalization, patients hospitalized due to Covid-19 were tested against non-hospitalized participants with a positive test (Positive), or non-hospitalized participants with a test (Tested), or against all non-hospitalized participants (Population). For analyses of Covid-19 severity, patients requiring invasive respiratory support or patients who died from complications were tested against non-severe participants with a positive test (Positive), or non-severe participants with a test (Tested) or all non-severe participants (Population). For analyses of Covid-19 death, patients with Covid-19 death were tested against participants with a positive test (Positive), or participants with a test (Tested) or against all participants (Population).

Analyses

Each GWAS was conducted with SAIGE v0.38,[13] which controls for population stratification, relatedness and case-control imbalance, and adjusted for baseline age (at enrollment), sex and 10 genetic principal components. For the results uploaded to the GRASP portal, variants were filtered on imputation quality ($r^2 > 0.3$), minor allele count (MAC > 2), and minor allele frequency (MAF > 0.0001). However, for the results presented in this manuscript,

we applied a more stringent filter, and considered only well-imputed variants ($r^2 > 0.8$) and common variants (MAF > 0.01). After applying this filter, the lambda (genomic control factor) ranged from 0.991 to 1.027 in all 65 analyses of the 02.24.21 data release (**Table S2**), indicating no systematic inflation. For analyses prior to the June 18th 2020 release, we conducted analyses on participants of European ancestry only, and started adding new analyses stratified by sex and ancestry from June 18th 2020 onward. GWAS were stratified for EUR, AFR, SAS, and OTHERS ancestries, and an additional trans-ancestry GWAS combining all participants (labelled ALL) as well as GWAS combining non-European (nEUR) participants were performed.

Associations are either reported as odd ratios (OR) and 95% confidence intervals or as beta coefficients (β) and associated standard errors (SE). Linkage disequilibrium (LD) was estimated by squared correlation (r^2) using UKB EUR imputed data. To test 2 observed effects are equal, we used the Z statistic: $Z = \frac{b_1 - b_2}{\sqrt{SEb_1^2 + SEb_2^2}}$, with b_1 and b_2 corresponding to the observed effects and SEb_1 and SEb_2 the associated standard errors.

Annotation

For each analysis hosted on the portal, we provide comprehensive annotation for top results ($P < 1 \times 10^{-5}$) using ANNOVAR[14] and the RESTful API service provided by CADD v1.6.[15] We also retrieve known phenotype associations extracted from the GRASP[16] and EBI GWAS catalogs,[17] and known eQTLs extracted from GTeX v8[18] and other eQTL resources compiled from nearly 150 datasets (built upon the work of Zhang *et al*,[19] detailed in **Table S3**).

Replication

The 6 Covid-19hgi meta-analyses, release version 5, excluding the UKB and 23andMe datasets, were used for our replication efforts and include results for Covid-19 susceptibility (labelled C2), hospitalization (B2) and severity (A2). The 3 meta-analyses restricted to European individuals (EUR) were used to replicate signals observed in our GWAS involving European UKB participants, while the remaining 3 trans-ancestry meta-analyses (ALL) were used to replicate signals observed either in our trans-ancestry GWAS or in non-European analyses. A signal was defined as replicated if the effect direction was concordant in the GWAS and the Covid-19hgi meta-analysis, and if the p-value in the meta-analysis was below 0.1, corresponding to a one-sided test threshold of 0.05. In addition, the Bonferroni method was applied to correct for multiple testing.

Data Availability

Permission was obtained to post UKB summary statistics under an approved application (ID 28525). The association results are available on the portal, as well as annotated top results. In addition to UKB summary statistics, results from other efforts are also hosted on the portal. Authors of Covid-19 GWAS publications have been contacted to seek approval before hosting the results of their analyses on the GRASP Covid-19 portal. Summary statistics at this time include multiple releases of the Covid-19hgi group, severe hospitalization results from Ellinghaus *et al*[6] and the GenOMICC study,[7] with all results are being re-annotated in the common framework mentioned above.

Results

UK Biobank Covid-19 demographics

Using the latest UKB data release available at this point, analyzed on February 24th 2021, we retrieved 47,413 participants with a Covid-19 diagnostic, of which 15,738 tested positive. According to inpatient care data, 1,916 positive cases were hospitalized, while 935 patients with severe Covid-19 diagnostic received respiratory support and/or died from complications (**Table 1**). Since May 7th 2020, we analyzed 15 UKB data releases regarding Covid-19 susceptibility, 7 data releases concerning Covid-19 related deaths, and 4 data releases for both Covid-19 related hospitalization and Covid-19 severity. Amongst Covid-19 positive participants, we observed a global increase in the percentage of female cases, starting at 45.3% at the first release analyzed, and reaching 52.47% in the last, while men were more likely to be infected ($P = 9.94 \times 10^{-7}$), hospitalized ($P = 1.34 \times 10^{-39}$), or develop severe complications ($P = 3.40 \times 10^{-29}$) and die from Covid-19 ($P < 10^{-300}$) in the 02.24.21 data release (**Table S4**). There was also a decrease in the mean age of positive cases, ranging from 57.02 to 53.77, with a significant drop after the 2020 summer (**Table 2**), with younger individuals more likely to be infected ($P < 10^{-300}$) while increase in age was associated with hospitalization ($P = 1.23 \times 10^{-73}$), severity ($P = 1.41 \times 10^{-93}$) and death ($P = 3.40 < 10^{-300}$) (**Table S4**). Positive cases were mainly of European ancestry, representing 85.5% of all Covid-19 positive participants in the first analysis and growing to 89.3% in the last. South Asian ancestry, African ancestry, and other ancestry represent 4.4%, 3.2% and 3.1% of positive cases, respectively, in this UKB data release. However, compared to

European participants, non-European participants were more likely to be infected ($P = 9.34 \times 10^{-37}$ for AFR, $P = 6.68 \times 10^{-82}$ for SAS, $P = 4.31 \times 10^{-8}$ for OTHERS), hospitalized ($P = 2.78 \times 10^{-28}$ for AFR, $P = 2.23 \times 10^{-9}$ for SAS, $P = 1.01 \times 10^{-6}$ for OTHERS), severe ($P = 2.89 \times 10^{-19}$ for AFR, $P = 9.84 \times 10^{-4}$ for SAS, P = 0.02 for OTHERS) and deceased participants ($P = 2.72 \times 10^{-10}$ for AFR, $P = 7.04 \times 10^{-3}$ for SAS) (**Table S4**).

Associations with Covid-19 susceptibility

The genome-wide significant loci in the last data release analyzed (on 02.24.21) for Covid-19 susceptibility are presented in **Table 3**, while all associations with $P < 10^{-5}$ are available in **Table S5**. In addition, all signals reaching genome-wide significance in any data release analyzed are presented in **Figures S1-S18**.

This project started with the analysis of Covid-19 susceptibility in participants of European ancestry, as the largest ancestry group in UKB. Consequently, it is the most repeated analysis with 15 iterations. With untested or negatively tested participants as controls (Population controls), 8 signals reached genome-wide significance ($P < 5 \times 10^{-8}$) at some point (**Figure 1**), of which only 3 remained significant in the last data release analyzed: the chr3p21.31 locus encompassing *SLC6A20* and several chemokine receptors (rs73062389-A, MAF = 0.06, OR = 1.22 [1.16; 1.29], $P = 7.64 \times 10^{-14}$), the *ABO* locus on chromosome 9 (rs9411378-A, MAF = 0.22, OR = 1.10 [1.07; 1.14], $P = 7.36 \times 10^{-10}$) and intronic variants located in *SCRT2* and *SRXN1* [MIM: 617583] on chromosome 20 (rs749199237-del.G, MAF = 0.35, OR = 1.08 [1.05; 1.11], $P = 1.29 \times 10^{-8}$). The chr3p21.31 and *ABO* loci were previously reported to modulate Covid-19 susceptibility,[6–8,10] while the third signal on chromosome 20 was novel.

198 Amongst the 5 other signals no longer significant in this data release, the *APOE* [MIM:
199 107741] variant tagging for the APOE-ε4 haplotype (rs429358-C, MAF = 0.15, OR = 1.38 [1.24;
200 1.53], P = 1.80×10^{-9}, on 07.14.20) was the only signal previously described,[20] and was notably
201 the first report of a genetic determinant for Covid-19 susceptibility. However, this previous
202 report was based on UKB data and this signal was not replicated in an independent dataset.
203 This association was greatly attenuated after the summer, when the number of Covid-19 cases
204 started to rise significantly and the mean age of infected participants decreased. The
205 interaction between age of participants and the *APOE* variant was significant (P = 3.4×10^{-6})
206 suggesting that a subset of older participant carriers of this variant was more at risk of Covid-19
207 infection. Remarkably, in the 02.24.21 data release, this variant is still suggestively associated
208 with Covid-19 severity (OR = 1.42 [1.24; 1.62], P = 4.36×10^{-7} in EUR) and death (OR = 1.45
209 [1.25; 1.67], P = 4.62×10^{-7} in EUR) suggesting a mechanism leading to lethal complications
210 after infection.

211 Using negatively tested participants as controls (Tested controls), the only signal
212 reaching genome-wide significance in this last data release was again the chr3p21.31 locus (P =
213 1.85×10^{-9}) with a different lead variant (rs73062394-T, MAF = 0.059, OR = 1.2 [1.13; 1.28]).
214 This variant was in moderate linkage disequilibrium (LD) with rs73062389 (r^2 = 0.59), which was
215 the second lead variant (P = 8.46×10^{-9}) for this analysis.

216 In other ancestry-stratified GWAS (AFR, SAS and OTHERS), no signal was found genome-
217 wide significant in the last data release analyzed. However, in the GWAS combining all non-
218 European participants, with Population controls, one signal was found significant at the *LRMDA*
219 [MIM: 614537] locus on chromosome 10 (rs114026383-C, MAF = 0.02, OR = 2.42 [1.78; 3.29], P

220 = 1.82×10^{-8}). According to gnomAD (v2.1.1),[21] this variant is mostly carried by individuals of
221 African ancestry (MAF = 0.04) and mainly absent in other ancestries. In the GWAS of African
222 ancestry participants, this signal is close to genome wide significance (P = 3.24×10^{-7}).
223 Interestingly, *LRMDA* variants have been found associated to lung function[22] [MIM: 608852]
224 and HIV viral load in an unadjusted GWAS,[23] but there was no evidence of LD between these
225 variants and rs114026383 ($r^2 < 0.01$).

226 Finally, in the trans-ancestry analyses combining all UKB participants, using the
227 Population controls, the signals at the chr3.p21.31 and *ABO* loci were also genome-wide
228 significant (rs73062389-A, P = 3.99×10^{-13} and rs9411378-A, P = 1.12×10^{-9}, respectively), and a
229 third signal was observed at the *MIR3681HG* locus on chromosome 2 (rs112938622-G, MAF =
230 0.22, OR = 1.08 [1.05; 1.12], P = 4.95×10^{-8}). When using Tested controls, only the chr3p21.31
231 signal was genome-wide significant in the last analysis (rs73062394-T, P = 1.99×10^{-8}).

232 In sex-stratified analyses, using Population controls, the chr3p21.31 signal was
233 significant in women (rs73062389-A, P = 1.06×10^{-8} in EUR and P = 1.35×10^{-8} in the trans-
234 ancestry GWAS) and highly associated in men (P = 1.12×10^{-6} in EUR and P = 3.19×10^{-6} in the
235 trans-ancestry GWAS), whereas the *ABO* signal was significant in men (rs9411378-A, P = $2.00 \times$
236 10^{-8} in EUR and P = 2.05×10^{-8} in the trans-ancestry GWAS) and moderately associated in
237 women (P = 1.51×10^{-3} in EUR and P = 1.89×10^{-3} in the trans-ancestry GWAS). Notably, the
238 observed effect of the *ABO* signal was significantly stronger in men (β = 0.135, SE = 0.023 in
239 EUR) than in women (β = 0.068, SE = 0.021), using the Z-test for the equality of regression
240 coefficients (P = 0.015). In addition, when using Tested controls, an intergenic variant at the
241 chr15q24.2 locus was significant in the trans-ancestry GWAS of women (rs71401691-G, MAF =

242 0.07, OR = 1.23 [1.14; 1.32], P = 4.72×10^{-8}), but not in men (P = 0.89). According to GTeX, the
243 effect allele increases the transcription levels of *MAN2C1* (Mannosidase Alpha Class 2C Member
244 1, [MIM: 154580]) in several tissues including lungs (P = 6.7×10^{-14}) and esophagus-mucosa (P =
245 3.4×10^{-10}).

246 Several signals were genome-wide significant in analyses using a specific set of controls,
247 but were below the significance threshold when using another one. Notably, the *LRMDA* signal
248 had a stronger effect in the Population analysis (β = 0.88, SE = 0.16) than in the Tested analysis
249 (β = 0.62, SE = 0.16) and the intergenic variant at the chr15q24.2 locus had a stronger effect in
250 the Tested analysis (β = 0.20, SE = 0.04) than in the Population analysis (β = 0.13, SE = 0.03), as
251 represented in **Figure S19**. However, the difference in effects when using 2 different set of
252 controls was not significant when applying the Z-test for the equality of regression coefficients
253 (P > 0.05).

254

255 Associations with Covid-19 hospitalization, severity, and death

256 The genome-wide significant findings for Covid-19 hospitalization, severity and death
257 are presented in **Table 4**, while all associations with P < 10^{-5} are available in **Table S6**. Similarly
258 to the susceptibility analyses, all signals reaching genome-wide significance in any analysis are
259 presented in **Figures S20-S42**. Across all analyses of hospitalization and severity, we identified 4
260 loci reaching genome-wide significance in the last data release analyzed, while no significant
261 signal was observed in the GWAS of Covid-19 related death.

262 The most recurring signal is again located at the known chr3p21.31 locus. Depending on
263 the analysis, we observed 3 distinct leads variants at this locus: rs13071258 in the GWAS of

264 hospitalized Europeans, rs72893671 in the trans-ancestry hospitalization GWAS, and
265 rs13092887 in the severe Covid-19 GWAS of both Europeans and all ancestries. However, all 3
266 variants were in LD (r^2 > 0.84), suggesting a single haplotype modulating Covid-19
267 hospitalization and severity. As previously reported,[8] this haplotype seems distinct from the
268 signal of Covid-19 susceptibility (**Figure S43**), as the 2 susceptibility variants (rs73062389 and
269 rs73062394) are not in LD (r^2 < 0.01) with the 3 severity variants.

270 The 3 remaining signals were not previously reported, and were identified in sex-
271 stratified analyses. First, intronic variants in *ANKS1A* [MIM: 608994] were observed significantly
272 associated in several analyses of men with Covid-19-related hospitalization, for instance in EUR
273 using non-hospitalized participants with a positive test as controls (rs112887370-T, MAF = 0.02,
274 OR = 3.30 [2.18; 5.00], P = 1.71×10^{-8}). According to GTeX, this allele increases the transcript
275 levels of the nearby gene *C6orf106* [MIM: 612217] in some tissues (thyroid, P = 1.5×10^{-7} and
276 testis, P = 1.7×10^{-6}), while other alleles in LD also reaching genome-wide significance (e.g.
277 rs2504165-T, OR = 2.84 [1.96; 4.12], P = 3.99×10^{-8}, r^2 = 0.73) can decrease the transcript levels
278 of *C6orf106* in skeletal muscles (P = 3.2×10^{-5}). *C6orf106* is also known as *ILRUN* (Inflammation
279 and Lipid Regulator with UBA-like and NBR-1-like domains), a gene involved in the regulation of
280 antiviral response. Second, an intergenic indel located at the chr12p13.31 locus, between
281 *CD163* [MIM: 605545] and *APOBEC1* [MIM: 600130], was associated with the hospitalization of
282 women when using non-hospitalized participants with a positive test (rs370732090-ins.ATTAT,
283 MAF = 0.14, OR = 0.61 [0.52; 0.73], P = 3.37×10^{-8}). Finally, an intronic insertion-deletion
284 located in *ADGRE1* [MIM: 600493] was associated with Covid-19 severity in European women,

using participants without severe Covid-19 as controls (rs770180814-ins.GT, MAF = 0.22, OR = 1.78 [1.45; 2.19], P = 4.51×10^{-8}).

Replication of novel genome-wide significant signals

The 7 novel signals identified were further investigated using the Covid-19hgi meta-analyses results, where the UKB was not included. Unfortunately, variants constituting the *LRMDA* and *APOBEC1* signals were absent from the meta-analyses, which prevented our effort to replicate these 2 signals. Out of the 5 remaining signals, 4 did not reach nominal significance in the replication datasets: at the *SCRT2* locus (rs749199237, P = 0.97 in C2 EUR), at the *MIR3681HG* locus (rs112938622, P = 0.27 in C2 ALL), at the chr15q24.2 locus (rs71401691, P = 0.82 in C2 ALL) and at the *ADGRE1* locus (rs770180814, P = 0.55 in A2 EUR). Finally, at the *ANKS1A* locus, the lead variant identified in the analysis of hospitalized Europeans men did not replicate (rs112887370, P = 0.14 in B2 EUR) but another variant in LD mentioned earlier was associated at nominal significance (rs2504165-T, OR = 1.13 [1.00; 1.28], P = 0.04 in B2 EUR). Unfortunately, this association does not survive multiple-testing correction, with a threshold for significance set at P < 0.017 for 6 one-sided tests. However, the *ANKS1A*, *ADGRE1* and chr15q24.2 signals were identified in sex-stratified analyses, and the possibility for replication in an independent sex-stratified dataset is not yet provided by Covid-19hgi.

Signals with suggestive significance trends

The significance trajectory of the most robust signals, at the chr3p21.31 and *ABO* loci, mostly increased after the surge of new cases following the 09.08.20 data release (**Figure 1**).

After this date, the chr3p21.31 signal increased at each of the following 8 data release and reached genome-wide significance in the 11.03.20 release, while the ABO signal increased 5 times out of 8 and reached significance in the 01.04.21 release. In order to identify signals that may become significant in future releases, we extracted variants displaying similar positive trends in significance, meaning variants not yet genome-wide significant, but exhibiting an increase in significance since the 09.08.20 data release.

For each Covid-19 susceptibility GWAS, we extracted variants which had an increase in significance in at least 6 out of the 8 releases following the 09.08.20 data release, and reached $P < 10^{-5}$ in the last data release. For other Covid-19 phenotypes, considering that fewer data releases were available, we extracted variants which increased in significance in all consecutive releases, reaching the same significance threshold of $P < 10^{-5}$ in the last data release. After excluding genome-wide significant signals, 2,409 variants involved in 3,607 associations variants with suggestive trends were identified across all GWAS (**Table S7**).

Next, we sought to identify whether these signals with suggestive trends reached at least nominal significance ($P < 0.05$) in the Covid-19hgi meta-analyses. Only signals from the European and trans-ancestry GWAS were considered at this step, to match the corresponding Covid-19hgi meta-analyses. Signals with suggestive trends from Covid-19 susceptibility GWAS were sought for replication in the corresponding C2 (susceptibility) meta-analyses, while signals with trends from the hospitalization and severe Covid-19 GWAS were sought for replication in the B2 and A2 meta-analyses, respectively. In order to decrease the multiple-testing correction burden, we only extracted the lead variant at each locus, a locus being defined as a genomic region containing one or several variants with $P < 10^{-5}$ separated by less than 1Mb. As a result,

329 329 lead variants involved in 378 associations were extracted (**Table S8**), of which 18 had
330 concordant effects and reached nominal significance in the Covid-19-hgi meta-analyses (**Table**
331 **5**). After applying the multiple-testing Bonferroni correction, with one-sided hypothesis, only 2
332 signals passed the corrected significance threshold ($0.05*2/378 = 2.65 \times 10^{-4}$), both in trans-
333 ancestry analyses. The first signal had a positive significance trajectory in the hospitalization
334 GWAS (**Figure S44**) and is located 5Kb upstream of *ATP5PO* [MIM: 600828], encoding a part of
335 the ATP synthase complex. According to GTeX, the effect allele (rs12482569-A, MAF = 0.17, OR
336 = 1.22 [1.12; 1.33], $P = 6.28 \times 10^{-6}$) increases the transcript levels of *ATP5PO* in several tissues
337 including the lungs ($P = 4.6 \times 10^{-18}$) and the esophagus-mucosa ($P = 1.9 \times 10^{-11}$). The second
338 signal (rs2011959-A, MAF = 0.37, OR = 1.34 [1.18; 1.53], $P = 6.50 \times 10^{-6}$) had a positive trend in
339 the GWAS of men with severe Covid-19 (**Figure S45**), and is located 200 bp downstream of *CCL3*
340 [MIM: 182283], a pro-inflammatory cytokine, reported by numerous studies to have unusually
341 high levels in patients with severe Covid-19.[24–26]
342
343
344 Discussion and conclusions
345
346 This project was initiated with the major aim to share results of Covid-19 host genetics
347 analyses freely and rapidly on the GRASP portal, during a pandemic where new insights to
348 improve patient care and develop better treatments were greatly needed. A few months after
349 the first Covid-19 case was identified in the UK, we started to perform GWAS on each dataset
350 released by UKB between May 2020 and February 2021, and thus far examined genetic signals

associated with Covid-19 phenotypes across 15 data releases. This unique context allowed us to track the evolution of genetic associations over time, an approach rarely applied. While some works have examined the statistical properties of phased and nested case-control studies,[27,28] few studies have proposed using statistical trajectories over time in genetic analyses.

As a first major observation, the majority of signals which were observed in the first stages of the project did not sustain over time. For instance, the first genome-wide significant association observed in the GWAS of Covid-19 susceptibility in Europeans with rs34338189 as lead variant is not even nominally significant in the last release (P = 0.29). Another genome-wide significant signal was observed at the *APOE* locus, with a significance that increased in the first 4 data releases before decreasing continually in the subsequent releases. The lead variant at the *APOE* locus is coding in part for the APOE-ε4 haplotype, known to increase the risk of Alzheimer's disease [MIM: 607822], dementia, dyslipidemia and cardiovascular diseases [MIM: 617347] and is speculated to cause inflammation and cytokine storms.[29] Notably, the suggestive association of the *APOE* signal with severe Covid-19 could support this proposition. The evolution of the *APOE* signal over time could also be due to an initial higher prevalence of Covid-19 in nursing homes,[30] where dementia patients were at higher risk of being infected and spreading the virus due to living arrangements, and a poor understanding of transmission dynamics and appropriate safety guidelines early in the pandemic. Overall, the evolution of these signals suggests a change in the composition of cases over time, such as the diminution of age and increase of positively tested women in the later data releases, as well as the introduction of variant SARS-CoV2 strains. This change was most significant after the summer when a surge in new Covid-19 infections occurred.

373 The most robust findings from our study are the association of the chr3p21.31 and *ABO*
374 loci with Covid-19 susceptibility and a distinct signal at the chr3p21.31 locus associated with
375 Hospitalization and severe Covid-19. These observations corroborate several previous reports,[6–
376 8,10] although we also observed a significant difference in the effect of the *ABO* variant between
377 men and women. Sex-stratified analyses also allowed us to identify a novel association between
378 *ANKS1A* variants and hospitalization of men, which reached nominal significance in the Covid-
379 19hgi hospitalization meta-analysis. Interestingly, the variants comprising this signal can also
380 influence the expression of *ILRUN*, either as an upregulator or as a repressor, depending on the
381 tissue. This gene is involved in innate immunity and has been recently shown to act as an
382 antiviral factor in the context of SARS-CoV-2 infection, notably by downregulating the
383 expression of *ACE2* [MIM: 300335] and *TMPRSS2* [MIM: 602060], the main SARS-CoV-2 entry
384 receptors.[31] This role differs from a previous report demonstrating an antiviral effect in cells
385 infected with Hendra virus,[32] which could hint at diverse roles for this gene in the context of
386 viral infection.

387 We have developed an original strategy to identify associations displaying increased
388 significance over time, and identified hundreds of loci with a significance trajectory suggesting
389 potential future genome-wide significance. Amongst these signals, 2 of them replicated at
390 nominal p-value in the Covid-19hgi meta-analyses, including a variant downstream of *CCL3*
391 suggestively associated with Severe Covid-19 in women, a cytokine with a well established high
392 expression in severe Covid-19 cases.[24–26] The associations we observed changing through the
393 pandemic could reflect random effects or changes in statistical power, but some of the results
394 suggest changes due to potential gene-environment interactions such as age, underlying health

conditions (*APOE*) or sex makeup of cases exposed to or engaging in risk behavior. This indicates the general approach of iterative analysis and trends analyses for genetics during pandemics may have benefits in uncovering pathophysiologic clues. Additionally, other factors like predominant virus strains and changing treatment strategies through a pandemic might interact with host genetics, and be better understood by iterative analyses.

In summary, our host genomic analyses of Covid-19 have improved the comprehension of mechanisms involved in the infection and complications due to Covid-19 and we continue to perform and rapidly share these analyses with the research community. Our study has some limitations. Most importantly, our data and the work of others support large health disparities between EUR and non-EUR individuals related to COVID-19 throughout the ongoing pandemic. Despite an over-representation proportionally among cases and those with severe and fatal outcomes, the non-EUR component of UKB is a proportionally small sample limiting our statistical power to address population-specific genetic variants contributing to health outcomes. Moving forward we feel that having a diverse set of results with different phenotype definitions, sex-specific, ancestry-specific, and including external group summary statistics, all in a common genome reference and annotation framework may maximize the chance for new studies to cross-replicate or meta-analyze results as Covid-19 genetic studies continue to grow.

Description of Supplemental Data

Supplemental Data include 45 figures and 8 tables.

Declaration of Interests

The authors declare no competing interests.

Acknowledgments

All authors were supported by NIH Intramural Research Program funds. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. This research has been conducted using the UK Biobank Resource under Application Number 28525. UK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also had funding from the Welsh assembly government and the British Heart Foundation. All UKB analyses for this manuscript were conducted on the NIH Biowulf high performance computing cluster (https://hpc.nih.gov/). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. We also thank the NHLBI IT team for their help in keeping the GRASP portal up to date.

Web Resources

GTeX : https://gtexportal.org/home/

CADD : https://cadd.gs.washington.edu/

EBI GWAS catalog : https://www.ebi.ac.uk/gwas/

GRASP catalog : https://grasp.nhlbi.nih.gov/Overview.aspx

Covid-19hgi meta-analyses results : https://www.covid19hg.org/results/r5/

GnomAD : https://gnomad.broadinstitute.org/

Data and Code Availability

The datasets generated during this study are available at the GRASP Covid-19 portal: https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx

References

1. Connors, J.M., and Levy, J.H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood *135*, 2033–2040.

2. Tang, D., Comish, P., and Kang, R. (2020). The hallmarks of COVID-19 disease. PLoS Pathog. *16*, e1008536.

3. Kwok, A.J., Mentzer, A., and Knight, J.C. (2021). Host genetics and infectious disease: new tools, insights and translational opportunities. Nat. Rev. Genet. *22*, 137–153.

4. Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Nagashima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A., Moore, J.P., et al. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature *381*, 667–673.

5. Ciancanelli, M.J., Huang, S.X.L., Luthra, P., Garner, H., Itan, Y., Volpi, S., Lafaille, F.G., Trouillet, C., Schmolke, M., Albrecht, R.A., et al. (2015). Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science *348*, 448–453.

6. Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos, A., Invernizzi, P., Fernández, J., Prati, D., Baselli, G., Asselta, R., et al. (2020). Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N. Engl. J. Med. *0*, null.

7. Pairo-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A.D., Rawlik, K., Pasko, D., Walker, S., Parkinson, N., Fourman, M.H., Russell, C.D., et al. (2020). Genetic mechanisms of critical illness in Covid-19. Nature 1–1.

8. Shelton, J.F., Shastri, A.J., Ye, C., Weldon, C.H., Filshtein-Sonmez, T., Coker, D., Symons, A., Esparza-Gordillo, J., Aslibekyan, S., and Auton, A. (2021). Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat. Genet. 1–8.

9. Kosmicki, J.A., Horowitz, J.E., Banerjee, N., Lanche, R., Marcketta, A., Maxwell, E., Bai, X., Sun, D., Backman, J.D., Sharma, D., et al. (2021). Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. Am. J. Hum. Genet. *0*,.

10. Initiative, T.C.-19 H.G., and Ganna, A. (2021). Mapping the human genetic architecture of COVID-19 by worldwide meta-analysis. MedRxiv 2021.03.10.21252820.

11. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015). UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med. *12*, e1001779.

12. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and genomic data. Nature *562*, 203–209.

13. Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N., LeFaive, J., VandeHaar, P., Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat. Genet. *50*, 1335–1341.

14. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. *38*, e164–e164.

15. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J., and Kircher, M. (2019). CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. *47*, D886–D894.

16. Eicher, J.D., Landowski, C., Stackhouse, B., Sloan, A., Chen, W., Jensen, N., Lien, J.-P., Leslie, R., and Johnson, A.D. (2015). GRASP v2.0: an update on the Genome-Wide Repository of Associations between SNPs and phenotypes. Nucleic Acids Res. *43*, D799-804.

17. Buniello, A., MacArthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. *47*, D1005–D1012.

18. Aguet, F., Brown, A.A., Castel, S.E., Davis, J.R., He, Y., Jo, B., Mohammadi, P., Park, Y., Parsana, P., Segrè, A.V., et al. (2017). Genetic effects on gene expression across human tissues. Nature *550*, 204–213.

19. Zhang, X., Gierman, H.J., Levy, D., Plump, A., Dobrin, R., Goring, H.H.H., Curran, J.E., Johnson, M.P., Blangero, J., Kim, S.K., et al. (2014). Synthesis of 53 tissue and cell line expression QTL datasets reveals master eQTLs. BMC Genomics *15*, 532.

20. Kuo, C.-L., Pilling, L.C., Atkins, J.L., Masoli, J.A.H., Delgado, J., Kuchel, G.A., and Melzer, D. (2020). ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. J. Gerontol. A. Biol. Sci. Med. Sci. *75*, 1801–1803.

21. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. Nature *581*, 434–443.

22. Soler Artigas, M., Loth, D.W., Wain, L.V., Gharib, S.A., Obeidat, M., Tang, W., Zhai, G., Zhao, J.H., Smith, A.V., Huffman, J.E., et al. (2011). Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat. Genet. *43*, 1082–1090.

23. Ekenberg, C., Tang, M.-H., Zucco, A.G., Murray, D.D., MacPherson, C.R., Hu, X., Sherman, B.T., Losso, M.H., Wood, R., Paredes, R., et al. (2019). Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. J. Infect. Dis. *220*, 1325–1334.

24. Chua, R.L., Lukassen, S., Trump, S., Hennig, B.P., Wendisch, D., Pott, F., Debnath, O., Thürmann, L., Kurth, F., Völker, M.T., et al. (2020). COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. *38*, 970–979.

25. Hue, S., Beldi-Ferchiou, A., Bendib, I., Surenaud, M., Fourati, S., Frapard, T., Rivoal, S., Razazi, K., Carteaux, G., Delfau-Larue, M.-H., et al. (2020). Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome. Am. J. Respir. Crit. Care Med. *202*, 1509–1519.

26. Trump, S., Lukassen, S., Anker, M.S., Chua, R.L., Liebig, J., Thürmann, L., Corman, V.M., Binder, M., Loske, J., Klasa, C., et al. (2020). Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat. Biotechnol.

27. Van der Tweel, I., and van Noord, P.A. (2000). Sequential analysis of matched dichotomous data from prospective case-control studies. Stat. Med. *19*, 3449–3464.

28. Boessen, R., van der Baan, F., Groenwold, R., Egberts, A., Klungel, O., Grobbee, D., Knol, M., and Roes, K. (2013). Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements. Pharm. Stat. *12*, 366–374.

29. Numbers, K., and Brodaty, H. (2021). The effects of the COVID-19 pandemic on people with dementia. Nat. Rev. Neurol. *17*, 69–70.

30. Chen, M.K., Chevalier, J.A., and Long, E.F. (2021). Nursing home staff networks and COVID-19. Proc. Natl. Acad. Sci. U. S. A. *118*,.

31. Tribolet, L., Alexander, M.R., Brice, A.M., van Vuren, P.J., Rootes, C.L., Mara, K., McDonald, M., Bruce, K.L., Gough, T.J., Shi, S., et al. (2021). ILRUN downregulates ACE2 expression and blocks infection of human cells by SARS-CoV-2. J. Virol.

32. Deffrasnes, C., Marsh, G.A., Foo, C.H., Rootes, C.L., Gould, C.M., Grusovin, J., Monaghan, P., Lo, M.K., Tompkins, S.M., Adams, T.E., et al. (2016). Genome-wide siRNA Screening at Biosafety Level 4 Reveals a Crucial Role for Fibrillarin in Henipavirus Infection. PLoS Pathog. *12*, e1005478.

Figure Titles and Legends

Figure 1. Evolution of significant signals associated with covid-19 susceptibility in UKB participants of European ancestry, using Population as controls.



The top panel represents the evolution in significance of signals reaching genome wide significance at least once across all data releases analyzed in Europeans for Covid-19 susceptibility. The middle panel represent the mean age of cases in each data release. The bottom panel represent the number of cases in each data release.

Tables

Table 1. Sample sizes for each analysis, as of 02.24.21

Phenotype	Controls	Ancestry	Sex-stratified	Cases	Controls	Female Cases	Female Controls
Susceptibility	Test negative OR not tested (Population)	ALL	yes	15,738	471,582	8,258	255,971
		EUR	yes	14,054	445,196	7,396	241,903
		AFR		496	7,148	277	4,082
		SAS		693	8,724	300	4,031
		OTHERS		495	10,514	285	5,955
		nEUR		1,684	26,386	862	14,068
	Test negative (Tested)	ALL	yes	15,738	47,413	8,258	25,373
		EUR	yes	14,054	44,646	7,396	23,847
		AFR		496	809	277	501
		SAS		693	938	300	430
		OTHERS		495	1,020	285	595
		nEUR		1,684	2,767	862	1,526
Hospitalization	Not hospitalized (Population)	ALL	yes	1,916	485,404	735	263,494
		EUR	yes	1,712	457,538	655	248,644
		nEUR		204	27,866	80	14,850
	Tested, not hospitalized (Tested)	ALL	yes	1,916	61,235	735	32,896
		EUR	yes	1,712	56,988	655	30,588
		nEUR		204	4,247	80	2,308
	Test positive, not hospitalized (Positive)	ALL	yes	1,916	13,822	735	7,523
		EUR	yes	1,712	12,342	655	6,741
		nEUR		204	1,480	80	782
Severe Covid-19	Not severe (Population)	ALL	yes	935	486,385	320	263,909
		EUR	yes	848	458,402	283	249,016
	Tested, not severe (Tested)	ALL	yes	935	62,216	320	33,311
		EUR	yes	848	57,852	283	30,960
	Test positive, not severe (Positive)	ALL	yes	935	14,803	320	7,938
		EUR	yes	848	13,206	283	7,113
Death	Survivor (Population)	ALL		828	486,492	287	263,942
		EUR		758	458,492	258	249,041
	Tested, survivor (Tested)	ALL		828	62,323	287	33,344
		EUR		758	57,942	258	30,985
	Test positive, survivor (Positive)	ALL		828	14,910	287	7,971
		EUR		758	13,296	258	7,138

Table 2. Composition of the consecutive UK Biobank Covid-19 data releases

Release Date	Cases (tested positive)	Controls	% Tested Positive Females	Age Cases[a]
05.07.20[b]	1,029	486,291	45.29	57.02 (9.12)
05.25.20[b]	1,270	486,050	46.93	56.57 (9.25)
06.05.20	1,412	485,908	47.31	56.45 (9.23)
06.18.20	1,485	485,835	47.21	56.47 (9.19)
07.14.20	1,670	485,650	46.59	56.89 (9.14)
08.04.20	1,723	485,597	46.66	56.77 (9.11)
09.08.20	1,821	485,499	46.73	56.66 (9.10)
10.16.20	3,050	484,270	48.69	55.19 (9.09)
11.03.20	4,372	482,948	49.38	54.79 (8.95)
11.25.20	5,868	481,452	49.52	54.56 (8.88)
12.04.20	7,435	479,885	50.46	54.36 (8.80)
01.04.21	8,722	478,598	50.50	54.28 (8.79)
01.22.21	13,401	473,919	52.27	53.85 (8.66)
02.02.21	14,802	472,518	52.44	53.81 (8.64)
02.24.21	15,738	471,582	52.47	53.77 (8.63)

[a] Mean baseline Age (standard deviation), at recruitment
[b] For the first 2 releases, the numbers reflect all ancestries, but only cases and controls of European ancestry were considered for analyses

Table 3. Lead variants associated with Covid-19 susceptibility (on 02.24.21)

Ancestry:Controls(:Sex)[a]	CHR:POS:NEA:EA	rsid	EAF	OR	±95CI	P (02.24.21)	Locus
ALL:Population	2:12594718:A:G	rs112938622	0.220	0.92	[0.90; 0.95]	4.95E-08	*MIR3681HG*
ALL:Population	3:45835417:G:A	rs73062389	0.058	1.21	[1.15; 1.27]	3.99E-13	*SLC6A20*
ALL:Population:F	3:45835417:G:A	rs73062389	0.058	1.22	[1.14; 1.31]	1.35E-08	*SLC6A20*
EUR:Population	3:45835417:G:A	rs73062389	0.060	1.22	[1.16; 1.29]	7.64E-14	*SLC6A20*
EUR:Population:F	3:45835417:G:A	rs73062389	0.060	1.23	[1.15; 1.32]	1.06E-08	*SLC6A20*
ALL:Tested	3:45839176:A:T	rs73062394	0.057	1.19	[1.12; 1.26]	1.99E-08	*SLC6A20;LZTFL1*
EUR:Tested	3:45839176:A:T	rs73062394	0.059	1.20	[1.13; 1.28]	1.85E-09	*SLC6A20;LZTFL1*
ALL:Population	9:136145425:C:A	rs9411378	0.219	1.10	[1.06; 1.13]	1.12E-09	*ABO*
ALL:Population:M	9:136145425:C:A	rs9411378	0.219	1.14	[1.09; 1.19]	2.00E-09	*ABO*
EUR:Population	9:136145425:C:A	rs9411378	0.222	1.10	[1.07; 1.14]	7.36E-10	*ABO*
EUR:Population:M	9:136145425:C:A	rs9411378	0.222	1.14	[1.09; 1.20]	2.05E-09	*ABO*
nEUR:Population	10:78250184:T:C	rs114026383	0.016	2.42	[1.78; 3.29]	1.82E-08	*LRMDA*
ALL:Tested:F	15:75602162:A:G	rs71401691	0.069	1.23	[1.14; 1.32]	4.72E-08	*GOLGA6D;COMMD4*
EUR:Population	20:651103:CG:C	rs749199237	0.350	1.08	[1.05; 1.11]	1.29E-08	*SCRT2*

[a] Indicate the ancestry by label, the control set, and, when it is the case, the corresponding sex-stratified analyses (F: Females, M: Males)
CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; EAF: Effect Allele Frequency; OR: Odd-ratio; ±95CI: 95% confidence interval [lower bound; upper bound]; P: P-value (from the last data release, analyzed on 02.24.21)

Table 4. Lead variants associated with Covid-19 hospitalization, severity, or death (on 02.24.21)

Phenotype	Ancestry:Controls(:Sex)[a]	CHR:POS:NEA:EA	rsid	EAF	OR	±95CI	P (02.24.21)	Locus
Hospitalization	EUR:Population	3:45843242:G:A	rs13071258	0.071	1.47	[1.29; 1.69]	3.18E-08	*SLC6A20;LZTFL1*
Hospitalization	EUR:Tested	3:45843242:G:A	rs13071258	0.071	1.49	[1.29; 1.71]	2.03E-08	*SLC6A20;LZTFL1*
Hospitalization	ALL:Population	3:45850783:T:A	rs72893671	0.081	1.43	[1.27; 1.61]	6.04E-09	*SLC6A20;LZTFL1*
Hospitalization	ALL:Tested	3:45850783:T:A	rs72893671	0.083	1.45	[1.29; 1.64]	1.99E-09	*SLC6A20;LZTFL1*
Severe	ALL:Population	3:45909644:C:A	rs13092887	0.075	1.72	[1.43; 2.07]	1.01E-08	*LZTFL1*
Severe	ALL:Tested	3:45909644:C:A	rs13092887	0.076	1.72	[1.43; 2.08]	1.04E-08	*LZTFL1*
Severe	EUR:Population	3:45909644:C:A	rs13092887	0.076	1.73	[1.43; 2.10]	2.38E-08	*LZTFL1*
Severe	EUR:Tested	3:45909644:C:A	rs13092887	0.076	1.73	[1.42; 2.09]	2.72E-08	*LZTFL1*
Hospitalization	ALL:Positive:M	6:34866730:G:C	rs112018241	0.015	3.10	[2.10; 4.60]	1.56E-08	*ANKS1A*
Hospitalization	ALL:Tested:M	6:35042053:C:T	rs112887370	0.015	2.89	[1.98; 4.21]	3.35E-08	*ANKS1A*
Hospitalization	EUR:Positive:M	6:35042053:C:T	rs112887370	0.015	3.30	[2.18; 5.00]	1.71E-08	*ANKS1A*
Hospitalization	EUR:Tested:M	6:35042053:C:T	rs112887370	0.014	3.16	[2.11; 4.76]	3.19E-08	*ANKS1A*
Hospitalization	EUR:Positive:F	12:7800075:A:ATTAT	rs370732090	0.857	0.61	[0.52; 0.73]	3.37E-08	*CD163;APOBEC1*
Severe	EUR:Population:F	19:6921713:G:GT	rs770180814	0.223	1.78	[1.45; 2.19]	4.51E-08	*ADGRE1*

[a] Indicate the ancestry by label, the control set, and, when it is the case, the corresponding sex-stratified analyses (F: Females, M: Males)
CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; EAF: Effect Allele Frequency; OR: Odd-ratio; ±95CI: ±95% Confidence interval [lower bound; upper bound]; P: P-value (from the last data release, analyzed on 02.24.21)

Table 5. Suggestive trends with p < 0.05 in Covid-19hgi meta-analyses

			UK Biobank GWAS			Covid-19hgi Meta-analysis			
CHR:POS:NEA:EA	**rsid**	**EAF**	**Phenotype:Ancestry: Controls(:Sex)[a]**	**OR.022421**	**P.022421**	**Meta-analysis**	**OR**	**P**	**Locus**
21:35293087:G:A	rs12482569	0.171	Hospitalization:ALL: Population	1.22	6.28E-06	B2_ALL	1.09	1.39E-04	*ATP5PO; LINC00649*
17:34415356:C:A	rs2011959	0.374	Severe:ALL:Positive:M	1.34	6.50E-06	A2_ALL	1.14	2.63E-04	*CCL3*
10:134354639:T:C	rs4880413	0.623	Hospitalization:ALL: Positive:M	1.25	7.05E-06	B2_ALL	1.05	0.018	*INPP5A*
1:63495201:T:C	rs79265284	0.022	Hospitalization:ALL: Positive:M	2.08	9.80E-06	B2_ALL	1.17	0.021	*LINC01739; LINC00466*
21:34156633:T:C	rs12627142	0.270	Susceptibility:EUR: Tested:M	1.11	5.92E-06	C2_EUR	1.03	0.024	*C21orf62-AS1*
8:138805432:G:A	rs6577840	0.899	Severe:ALL:Positive:M	1.74	1.10E-07	A2_ALL	1.12	0.025	*LOC101927915; LOC401478*
8:138803782:T:C	rs7835023	0.904	Severe:EUR:Positive:M	1.72	9.10E-07	A2_EUR	1.15	0.032	*LOC101927915; LOC401478*
10:134354639:T:C	rs4880413	0.624	Hospitalization:EUR: Positive:M	1.27	2.96E-06	B2_EUR	1.05	0.032	*INPP5A*
14:34041605:T:C	rs143195932	0.013	Hospitalization:EUR: Positive:M	3.41	6.48E-06	B2_EUR	1.29	0.032	*NPAS3*
10:37877569:T:C	rs4934590	0.293	Severe:EUR: Population:M	1.38	1.34E-06	A2_EUR	1.10	0.042	*LINC00993; MTRNR2L7*
5:17189240:G:A	rs188950364	0.019	Severe:ALL:Tested:M	3.21	3.57E-07	A2_ALL	1.22	0.042	*BASP1-AS1*
9:90051212:T:C	rs17052840	0.086	Severe:EUR: Population:F	2.05	5.72E-06	A2_EUR	1.12	0.043	*LINC02872; DAPK1*
21:34156633:T:C	rs12627142	0.270	Susceptibility:ALL: Tested:M	1.11	3.26E-06	C2_ALL	1.02	0.044	*C21orf62-AS1*
1:203193134:T:G	rs2486068	0.185	Severe:ALL: Population:M	1.42	4.01E-06	A2_ALL	1.09	0.046	*CHIT1*
15:101940428:G:A	rs1552946	0.732	Severe:EUR: Tested:F	0.64	5.64E-06	A2_EUR	0.92	0.048	*PCSK6*
22:28624425:T:C	rs28701638	0.160	Severe:EUR:Positive	0.73	9.63E-06	A2_EUR	0.92	0.048	*TTC28*
5:92032219:G:A	rs17082483	0.090	Severe:ALL:Positive:M	1.77	4.26E-07	A2_ALL	1.09	0.048	*ARRDC3-AS1; NR2F1-AS1*
4:27510227:A:T	rs4377577	0.164	Susceptibility:ALL: Population:F	1.10	8.86E-06	C2_ALL	1.03	0.048	*LINC02261; MIR4275*

[a] Indicate the phenotype, the ancestry, the control set, and, when it is the case, the corresponding sex-stratified analyses (F: Females, M: Males)

CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; EAF: Effect Allele Frequency; P: P-value